The role of non-coding RNA regulates stem cell programmed death in disease therapy
Liao Z., Liu W., Wang L., Xie W., Yao C., Huang Q.
Narrative Review, published in Noncoding RNA Res (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Noncoding RNA Res (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40454168
- PMCID
- PMC12123353
- DOI
- 10.1016/j.ncrna.2025.04.005
- Citations
- 7
Abstract (original English)
Programmed cell death (PCD), an essential and inevitable phenomenon, is integral to organismal development. It not only maintains cellular homeostasis but also prevents aberrant cell proliferation, thereby protecting normal growth and development from detrimental factors. And it is governed by a highly complex and sophisticated regulatory network in which non-coding RNAs (ncRNAs) play pivotal roles. ncRNAs refer to RNA molecules that do not encode proteins and encompass various types, including long non-coding RNA (lncRNA), microRNA (miRNA), and circular RNA (circRNA). Herein, we investigate the specific signaling mechanisms by which ncRNAs regulate stem cells, elucidating their role in modulating PCD process through interactions with specific molecules. We further summarize the impact of above modulating role on stem cell differentiation, proliferation, cycle regulation and diverse disease development and therapy. Additionally, given the emerging trends in the therapeutic application of ncRNAs and stem cells, we explore the potential of their combined application for disease treatment.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.